澳大利亚真实世界中使用乌帕替尼治疗重度特应性皮炎的经验。
A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis.
机构信息
Department of Dermatology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
出版信息
Australas J Dermatol. 2023 Nov;64(4):e352-e356. doi: 10.1111/ajd.14139. Epub 2023 Jul 31.
Upadacitinib is a selective Janus kinase-1 (JAK-1) inhibitor that has been shown in clinical trials to be effective for the treatment of moderate-to-severe atopic dermatitis (AD). This study aimed to evaluate the real-world experience of patients with AD treated with upadacitinib in a single-centre Australian cohort. Our study revealed a higher propensity for herpetic infections compared with previous randomised controlled trials (RCTs).
乌帕替尼是一种选择性 Janus 激酶-1（JAK-1）抑制剂，临床试验已证明其对中重度特应性皮炎（AD）的治疗有效。本研究旨在评估澳大利亚单中心队列中接受乌帕替尼治疗的 AD 患者的真实世界经验。与之前的随机对照试验（RCT）相比，我们的研究显示疱疹感染的倾向性更高。
Zotero 插件